Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease

Diabetes

Volumn 46, Issue 5, 1997, Pages 860-867

  Alessi, M C ^a   Peiretti, F ^a   Morange, P ^a   Henry, M ^a   Nalbone, G ^a   Juhan Vague, I ^a,b  

^a INSERM   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INSULIN RESISTANCE; OBESITY; OMENTUM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SUBCUTANEOUS FAT; TISSUE DISTRIBUTION;

EID: 0030975615     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.5.860     Document Type: Article

References (69)

1. Reilly CP, Fujita T, Hutzelmann JE, Mayer EJ, Shebuski RJ: Plasminogen activator inhibitor 1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism. Circulation 84:287-292, 1991
2. Vaughan DE, Declerck PJ, Van Houtte E, de Mol M, Collen D: Reactivated recombinant plasminogen activator inhibitor 1 (r PAI-1) effectively prevents thrombolysis in vivo. Thromb Haemostas 68:60-63, 1992
3. Biemond BJ, Levi M, Coronel R, Janse MJ, Ten Cate JW, Pannekoek H: Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effect of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 91:1175-1181, 1995
4. Charlton PA, Faint RW, Bent F, Bryans J, Mackie I, Machin S, Bevan P: A series of low molecular weight inhibitors of plasminogen activator inhibitor (PAI-1) increase fibrinolysis and protect against thrombus formation in the rat (Abstract). Thromb Haemostas 73:1005, 1995
5. Carmeliet P, Stassen JM, Schoojans L, Ream B, van der Oord JJ, de Mol M, Mulligan RC, Collen D: Plasminogen activator inhibitor 1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 92:2756-2760, 1993
6. Carmeliet P, Bouche A, De Clercq C, Janssen S, Pollefeyt S, Wyns S, Mulligan RC, Collen D: Biological effects of disruption of the tissue-type plasminogen activator, urokinase type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 748:367-382, 1995
7. Juhan-Vague I, Alessi MC: Fibrinolysis and risk of coronary artery disease. Fibrinolysis 10:127-136, 1996
8. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii:3-7, 1987
9. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94:2057-2063, 1996
10. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
11. Desprès JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
12. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 35:250-253, 1986
13. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C: Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 38:913-915, 1989
14. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U: Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39:1044-1048, 1990
15. Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G: Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden. J Clin Epidemiol 42:719-723, 1989
16. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462, 1991
17. Juhan-Vague I, Thompson SG, Jespersen J: Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb 13:1865-1873, 1993
18. Eliasson M, Evrin PE, Lundblad D: Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure: the Northern Sweden MONICA Study. J Clin Epidemiol 47:513-524, 1994
19. Karpe F, Bavenholm P, Proudler A, Silveira A, Crook D, Blomback M, de Faire U, Hamsten A: Relationships of insulin and intact or split proinsulin to haemostatic function in young men with and without coronary artery disease. J Int Med 236:75-88, 1994
20. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 60:491-494, 1988
21. Kooistra T, Bosma PJ, Tons HAM, Van Den Berg AP, Meyer P, Princen HMG: Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 62:723-728, 1989
22. Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1: implications for vascular disease by hyperinsulinemic states. Proc Natl Acad Sci USA 88:9959-9963, 1991
23. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I: Plasminogen activator inhibitor 1 synthesis in the human hepatoma cell line Hep G2: metformin inhibits the stimulating effect of insulin. J Clin Invest 91:2185-2193, 1993
24. Alessi MC, Anfosso F, Henry M, Peiretti F, Nalbone G, Juhan-Vague I: Up-regulation of PAI-1 synthesis by insulin and proinsulin in Hep G2 cells but not in endothelial cells. Fibrinolysis 9:237-242, 1995
25. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J: Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10:1067-1073, 1990
26. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I: Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor 1 synthesis by endothelial cells. Arterioscler Thromb 11:1821-1829, 1991
27. Erickson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A: Allele specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855, 1995
28. Sironi L, Mussoni L, Prati L, Baldassarre D, Camera M, Banfi C, Tremoli E: Plasminogen activator inhibitor type 1 synthesis and mRNA expression in Hep G2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 16:89-96, 1996
29. Potter Van Loon BJ, de Bart ACW, Radder JK, Frolich M, Kluft C, Meindors AE: Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor 1 concentration in humans. Fibrinolysis 4:93-94, 1990
30. Raccah D, Alessi MC, Scelles V, Menart C, Juhan-Vague I, Vague P: Plasminogen activator inhibitor activity in various type of endogenous hypertriglyceridemia. Fibrinolysis 7:171-176, 1993
31. Folsom AR, Qamhieh HT, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, Wu KK: Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 13:162-169, 1993
32. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43:104-109, 1994
33. Alessi MC, Parrot G, Guenoun E, Scelles V, Vague P, Juhan-Vague I: Relation between plasma PAI activity and Adipsin levels. Thromb Haemostas 74:1200-1202, 1995
34. Sawdey S, Loskutoff DJ: Regulation of murine type 1 plasminogen activity inhibitor (PAI-1) gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor α and transforming growth factor β. J Clin Invest 8:346-1353, 1991
35. Samad F, Yamamoto K, Loskutoff DJ: Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. J Clin Invest 97:37-46, 1996
36. Lundgren CH, Brown SL, Nordt TD, Sobel BE, Fujii S: Elaboration of type 1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 93:106-110, 1996
37. Samad F, Loskutoff DJ: Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 2:568-582, 1997
38. Allawi J, Jarrett RJ: Male-type fat distribution is associated with cardiovascular risk factors and the prevalence of cardiovascular disease in non insulin treated diabetics. J Diabetes Complications 4:150-152, 1990
39. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L: Distribution of adipose tissue and risk of cardiovascular disease and death: 12 year follow-up of participants in the population study of women in Gothenburg, Sweden. Br Med J 289:1257-1261, 1984
40. Larsson B, Svärdsud DK, Welin L, Wilhelmsen L, Björntorp P, Tibbin G: Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br Med J 288:1401-1404, 1984
41. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G: Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 16:368-374, 1996
42. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med 2:800-803, 1996
43. Kissebah AH, Krakower GR: Regional adiposity and morbidity. Physiol Rev 74:761-811, 1994
44. Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK: Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 3:51-53, 1989
45. Velthuls-te Wierik EJM, Meijer P, Kluft C, Van Den Berg H: Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non obese men. Metabolism 44:1548-1552, 1995
46. Robdell M: Metabolism of isolated fat cells: effect of hormone on fat metabolism and lipolysis. J Biol Chem 239:375-380, 1964
47. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D: Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody, based on enzyme-linked immunoadsorbant assay. Blood 71:220-225, 1988
48. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
49. Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
50. Melton DA, Krieg PA, Rebagliati MR, Maniatis T, Zinn K, Green MR: Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucl Acid Res 2:7035-7056, 1984
51. O'Brien SN, Mantzke KA, Kilgore MW, Price TM: Relationship between stromal-vascular cells and adipocytes in human adipose tissue. Anal Quant Cytol Histol 18:137-143, 1996
52. Smith U: Morphological studies of human subcutaneous adipose tissue in vitro. Anat Rec 169:97-104, 1970
53. Moustaid N, Brynn HJ, Taylor JW: Insulin increases lipogenic enzyme activity in human adipocytes in primary cultures. J Nutr 126:865-870, 1996
54. Van den Berg EA, Sprengers ED, Jaye M, Burgess W, Maciag T, Van Hinsberg VWM: Regulation of plasminogen activator inhibitor 1 mRNA in human endothelial cells. Thromb Haemostas 60:63-67, 1988
55. Kern PA, Saghizadeh M, Ong JM, Borh RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue. J Clin Invest 5:2111-2119, 1995
56. Hotamisligil GS, Amer P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor in human obesity and insulin resistance. J Clin Invest 5:2409-2415, 1995
57. Van Hinsbergh VWM, Van den Berg EA, Fiers W, Dooijewaard G: Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 75:1991-1998, 1990
58. Van Hinsbergh VWM, Kooistra T, Scheffer MA, van Bockel JH, van Muijen GNP: Characterization and fibrinolytic properties of human omental tissue mesothelial cells: comparison with endothelial cells. Blood 75:1490-1497, 1990
59. Border WA, Ruoslahti E: Transforming growth factor beta in disease: the dark side of tissue repair. J clin Invest 90:1-7, 1992
60. Butterwith SC, Peddie CD, Goddard C: Regulation of adipocyte precursor DNA synthesis by acidic and basic fibroblast growth factors: interaction with heparin and other growth factors. J Endocrinol 137:369-374, 1993
61. Vassaux G, Negrel R, Ailhaud G, Gaillard D: Proliferation and differentiation of rat adipose precursor cells in chemically defined medium: differential action of antiadipogenic agents. J Cell Physiol 161:249-256, 1994
62. Tervel T, Valverde AM, Benito M, Lorenzo M: Transforming growth factor β1 induces mitogenesis in fetal brown adipocytes. J Cell Physiol 166:577-584, 1996
63. Keeton M, Curridon SA, Van Zonnevel AJ, Loskutoff DJ: Identification of regulatory sequences in the type 1 plasminogen activator inhibitor responsive to transforming growth factor β(TGFβ). J Biol Chem 266:23048-23052, 1991
64. Björntorp P: "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10:493-496, 1990
65. Considrine RV, Sihna MK, Heiman ML, Kriauciunas A, Stephens TN, Nyce MR, Ohanessian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295, 1996
66. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM: Leptin levels in human and rodent:measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med 1:1155-1161, 1995
67. Kluft C, Jie AFH, Rijken DC, Verheijen JH: Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast acting inhibitor (PAI-1). Thromb Haemostas 59:329-332, 1988
68. Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S, Marco C, Caro JF: Nocturnal rise of leptin in lean, obese, and non insulin dependent diabetes mellitus subjects. J Clin Invest 97:1344-1347, 1996
69. Leroy P, Dessolin S, Villageois P, Chun Moon B, Friedman JM, Ailhaud G, Dani C: Expression of ob gene in adipose cells: regulation by insulin. J Biol Chem 271:2365-2368, 1995